Introduction
Alzheimer's disease (AD) is the most common form of dementia, and the increase in the aging rate of developing countries portends a significant increase in its prevalence in coming years. A large portion of the world's public health expenditures is AD related, directly or indirectly (Alzheimer's Disease International, 2010). Furthermore, AD affects the quality of life of people afflicted with the disease and their family members, who are, in most of cases, their primary caregivers (Wimo et al., 2013) . Accordingly, effective strategies to prevent or to postpone AD onset are clearly needed. To date, only symptomatic treatments are available for AD, and these medications offer modest benefits without a curative impact (Herrmann et al., 2011) .
Regarding preventive strategies, several factors have been identified to estimate AD risk (i.e., age, sex, family history, the presence of the APOE4 allele, systolic blood pressure, body mass index, total cholesterol level, and physical activity) and several hypotheses to prevent AD have been postulated . Although there are many technical challenges in designing AD preventive trials, this remains a crucial area of research (Andrieu et al., 2009; Gauthier et al., 2012) .
Among the modifiable lifestyle-related factors associated with AD risk, diet has demonstrated some interesting results. Specifically, certain diets (e.g., Mediterranean-type diets) have been associated with a lower incidence of AD (Gardener et al., 2012; Sofi et al., 2010) . Two nutrition-related links could connect diet and the development of AD, that is, micronutrients and macronutrients (Bourre, 2006a (Bourre, , 2006b ). Deficiencies of some micronutrients, especially those related to antioxidant and amino acid metabolism mechanisms (e.g., vitamins B1, B2, B6, B12, C, and folate), have been associated with cognitive impairment in elderly people (Solfrizzi et al., 2011) . A high intake of specific dietary factors (e.g., saturated fatty acids) enhances the amyloid-beta (Ab) deposition in the animal model brain and increases oxidative stress (Solfrizzi et al., 2011) . The relationship between specific fats and AD risk may relate, at least in part, to the actions of APOE, which is involved in the transport and metabolism of lipids. In addition to nutrients, a number of neurotoxic substances are consumed through the diet. In some cases, these compounds have been associated with an increase in AD risk.
Metals in a diet can be considered both as neurotoxic compounds and as essential elements for a wide range of physiologic functions. In some cases, their ingestion is associated with the onset of neurotoxic effects. For instance, some studies have investigated the role that aluminum exposure plays in AD risk. Epidemiologic evidence suggests that aluminum in the diet may modify AD risk (Frisardi et al., 2010; Tomljenovic, 2011) . It has also been postulated recently that environmental exposure to lead may result in epigenetic changes associated with AD pathogenesis (Bakulski et al., 2012) . In some cases, the transition from a physiological condition to a pathologic one is precipitated by an altered state of metalrelated metabolism, especially in regard to transition metals, such as iron, copper, and zinc.
Regarding metal dyshomeostasis in AD, several research groups have hypothesized that alterations in metal metabolism are associated with an increase in metal-related oxidative stress, which contributes to Ab toxicity and Ab oligomer formation and precipitation. Following this line of thought, one of the most recent concepts in AD pathogenesis is that alterations of copper metabolism associated with genetic defects are associated with a "copper phenotype" in a large percentage of AD patients. This hypothesis, supported by recent evidence (Bonda et al., 2011; Squitti and Polimanti, 2013) , is changing the way scientists view AD. It also suggests unexpected routes for AD prevention. In fact, although scientists have yet to fully grasp how foods influence a person's risk of developing AD, a recent study has elucidated the detrimental effect of altered copper metabolism (copper dyshomeostasis) on AD .
The amount of literature available on dysfunction of copper metabolism has reached such a critical mass that dietary changes may be justified. In fact, these changes may be justified not only in cases in which available evidence demonstrates risk beyond any doubt but also in cases in which evidence of risk is substantial. Accordingly, individuals with an established diagnosis of copper dysfunction who choose to implement a low-copper diet may reduce their risk of AD. In this review, we describe the mechanisms of dietary copper intake and absorption, the relationship between defects in copper metabolism and human diseases, and the basic tenets of a low-copper diet.
Copper homeostasis
Copper homeostasis is determined by the equilibrium between the rates of dietary absorption from food and drinking water and excretion through stools and bile (Fig. 1) . The World Health Organization (WHO) has classified copper as an essential element with the following statement: "absence or deficiency of the element from the diet produces either functional or structural abnormalities and that the abnormalities are related to, or consequence of, specific biochemical changes that can be reversed by the presence of the essential metal" (WHO, 1996) . Excess copper can also lead to undesirable and life-threatening effects (de Romana et al., 2011) . Consequently, the equilibrium between the rates of copper absorption and copper excretion is tightly regulated.
Copper intake and absorption
According to the WHO, the minimal acceptable intake of copper is about 0.9e1.3 mg per day, whereas, the average person consumes w2 mg per day (WHO, 1996) . Ingesting 2e3 mg per day of copper is safe and adequately prevents copper deficiency. However, ingesting >5 mg per day is considered toxic. In a normal individual, ingestion of a higher quantity of copper has little or no effect on its absorption because under normal conditions, the amount of copper absorbed in the upper gastrointestinal tract is generally w0.5 mg per day (Hoogenraad, 2001 ) and the remaining amount of copper with respect to the quantity coming from dietary intake is directly eliminated without entering pathways of absorption. This occurs mainly through the use of metallothioneins, which function as a "mucosal block" for copper bioavailability. Copper absorption corresponds to w30% of an individual's copper intake; however, an elegant experiment in the late 1980s clearly demonstrated that copper absorption depends on dietary copper intake (Turnlund et al.,1989) . Specifically, copper absorption decreases as dietary copper intake increases, and it can vary from 0.43 mg per day (corresponding to 56% of the dietary copper intake during a low-copper regimen: 0.79 mg per day for 42 days) to 0.9 mg per day (corresponding to 12% under a high-copper regimen diet: 7.53 mg per day). At a high-copper intake regimen, the efficiency of copper absorption declines, but more copper is absorbed and retained (Turnlund et al., 2005) .
In the mucosal cells of the intestine, metallothioneins tightly bind copper and block its absorption. Copper is trapped in metallothioneins, and it is not transferred into the general circulation. The exfoliation of mucosal cells, when enterocytes are shed into the intestinal lumen and released with feces, allows for copper removal. This process occurs without depleting the bioavailable reservoir of copper. The expression of metallothioneins can be modulated by zinc, which can increase by 25-fold the expression of these natural coppertrapping proteins. In the upper gastrointestinal tract, copper is absorbed as lowemolecular-weight-soluble complexes of copper (Kim et al., 2003) . This copper fraction is mainly bound to amino acids, small peptides, micronutrients, and albumin. In this form, it is transported into the serum and released to be absorbed into the tissues. From the gut, this lowemolecular-weight copper, also known as "free," labile, or non-ceruloplasmin (non-Cp), reaches the liver through the portal circulation. The liver absorbs most of this copper and limits its concentration in the blood to 0.008e1.6 mmol/L that corresponds to 0.05e1 mg/dL. This is the normal reference range of non-Cp copper in serum after an overnight fast (Hoogenraad, 2001) .
The liver functions as a chemical laboratory for copper and processes this highly reactive metal with specialized proteins, which allows copper (Cu þ ) to enter the hepatocyte and pass through human copper transporter 1. These proteins then accompany the copper to the sites of utilization. In the hepatocyte, copper is incorporated into copper proteins and enzymes that regulate a number of vital biologic processes including cytochromes in the mitochondria for oxidative respiration, Cu/Zn superoxide dismutase for antioxidant defenses, Cp for regulating the iron oxidative state, and distribution to tissues and organs (for detailed molecular pathways, refer to Gaggelli et al., 2006; Squitti et al., 2013d) . The main pathway involved in copper balance in the hepatocyte also involves Cp and the key protein pump ATP7B. Copper enters the hepatocyte through human copper transporter 1 (CTR1), and it is subsequently bound by ATOX1, which transfers the metal to ATP7B that, in turn, mounts the copper into the nascent Cp in the trans-Golgi network. When copper exceeds the needs of the cell, ATP7B moves toward the cell membrane, and, via hepatic lysosomes, copper is released in the bile canaliculus together with the degradation products of Cp. ATP7B and Cp cooperate in regulating copper excretion and release copper complexes into the bile (Verbina et al., 1992) .
Copper excretion
The lowemolecular-weight copper leaves the gut and moves to the liver via the portal circulation. Given an absorption rate of 0.5 mg per day (that can range between 12% and 56%), approximately 0.2e0.5 mg of copper is released through the bile. The remaining copper is used for the Cp (200 mg/mL) and other copper protein biosynthesis. The majority of copper taken in through the diet, however, is not absorbed. Rather, it accumulates into metallothioneins and is directly expelled through stools. Excretion through urine is negligible and accounts for <0.05 mg per day. Turnlund et al. (1990) reported a value of copper in the sweat in the same order of magnitude as urinal copper losses. However, an earlier study found copper losses in sweat to be 10-fold greater and reported a value of w0.34 mg per day (Jacob et al., 1981) .
Copper metabolism and human diseases
Defects in the pathways controlling copper homeostasis result in serious health consequences, specifically for brain health and development. This is well exemplified by 2 genetic disorders that are alternately characterized by deficiency (Menkes disease [MD] ) and excess (Wilson disease [WD]) of total body copper content. In these diseases, the genes coding for the 2-membrane copper transport proteins known as copper pumps ATP7A and ATP7B are mutated (Kodama et al., 2012) .
Menkes disease
MD is the paradigmatic disease for copper deficiency. MD is caused by mutations in the ATP7A gene that encode for P-type copper-transporting ATPase 1 (ATP7A) (Bertini and Rosato, 2008) . This protein is widely expressed in human tissues and allows copper to enter into the bloodstream by passing through enterocytes. Mutations of ATP7A prevent copper absorption at the Fig. 1 . The normal pathway for copper absorption. Copper dietary intake in 24 hours is 1.5 mg; 0.5 mg per day of this copper is absorbed from duodenum and transported to the liver through the portal system. In the liver, the copper is structurally incorporated into ceruloplasmin (Cp) by the copper pump ATP7B. Normal values of Cp are >20 mg/dL; the concentrations of non-Cp copper and urinary copper after an overnight fast are <1.6 mmol/L. Red box indicates the hepatocyte. A still unknown reductase protein reduces Cu 2þ to Cu þ , which is then imported into the cell by human copper transporter 1 (hCTR1). Once in the cell, copper is carried by cytochrome C oxidase assembly homolog (COX17) to the mitochondria, by the copper chaperone for superoxide dismutase (CCS) to the superoxide dismutase (SOD) and by the antioxidant protein 1 homolog (ATOX1) to the ATP7B. In the trans-Golgi network (TGN), the ATP7B protein loads copper into nascent apo-Cp to form active holo-Cp.
intestinal level, which causes a copper deficiency and results in copper being poorly distributed to cells in the body. Copper accumulates in some tissues, that is, the small intestine and kidneys, whereas the brain and other tissues have unusually low levels . This abnormal copper distribution induces different clinical manifestations including growth failure and the deterioration of the nervous system (Kaler, 2011) . Signs of MD include weak muscle tone, sagging facial features, seizures, mental retardation, blue sclera, and developmental delay (Kaler, 1994) . The disease onset typically begins during infancy. In some cases, copper deficiency in MD is so severe that male fetuses die during gestation because MD is an X-linked recessive disorder (Tumer, 2013) . The neurologic symptoms of MD are likely caused by the localization of ATP7A in the brain. ATP7A is expressed in the polarized brain capillary endothelial cells of the blood-brain barrier. This copper pump is localized in the basolateral surfaces, which deliver copper from the blood to the brain (Choi and Zheng, 2009) . Moreover, ATP7A is highly expressed in choroid plexus epithelial cells, and ATP7A protein is thought to be localized at the apical membrane of these cells, which suggests that ATP7A plays a role in the delivery of copper to cerebrospinal fluid (CSF) (Choi and Zheng, 2009) .
Early diagnosis and treatment with copper intravenous infusion increase the likelihood of the survival of MD patients. However, therapy can normalize signs and symptoms of the disease only in patients with ATP7A mutations that have mild effects on the protein activity (Kaler, 2011) .
Wilson disease
WD is caused by a defect in copper excretion and is the paradigmatic disease of copper accumulation or intoxication. Defects of ATP7B cause copper overload and intoxication in the liver and then in the brain and other organs. The irises of afflicted patients are often encircled by Kayser-Fleischer rings because of copper accumulation in the cornea (Descemet membrane) (Fig. 2) . Kayser-Fleischer rings are 1 of the 6 markers used to suggest the WD diagnosis (Bakulski et al., 2012) . These markers are diagnostically important because the clinical presentation is variable and is influenced by additional hereditary factors. A case in point was reported in 1981, when researchers identified late-onset cases of WD among 5 family members, each of whom displayed different clinical symptoms, from a psychiatric manifestation, to hepatic disease, to neurologic symptoms, and even asymptomatic siblings (Czlonkowska and Rodo, 1981) . This example demonstrates the complexity of the diagnosis, the relevance of a biologic marker intended to identify the biologic lesion (non-Cp copper higher than the normal) rather than the clinical presentation, along with the relevance of the interplay between genetics and the diet and, generally, the lifestyle because the siblings were affected by the same ATP7B mutation. Evidence also suggests that the onset of WD usually occurs earlier in patients with hepatic symptoms than in those with neurologic manifestations, suggesting a dosage effect of copper intoxication that is inversely associated with the severity of the biologic lesion. When the lesion is more severe, it affects the liver acutely, and when it is less severe, it takes years or even decades to affect brain functionality. A defect in the ATP7B gene causes abnormal copper pumping through the trans-Golgi vesicles and impairment of copper incorporation into nascent Cp and copper excretion through the bile. Schematically, in WD, copper absorption is normal, but copper incorporation into Cp and bile excretion is defective. Accordingly, copper accumulates in the hepatocytes, and there is an excess of copper in the blood, thus increasing the concentration of non-Cp copper. Non-Cp copper values in normal individuals are <1.6 mmol/L after an overnight fast, but in WD-affected individuals, they are notably higher.
Except for specific cancers, acute inflammatory states, acute liver failure, and chronic cholestasis, no other altered biologic pathway can cause increased levels of non-Cp copper after an overnight fast. This enables researchers to identify a clear metabolic defect in the bottleneck step of the copper excretion pathway involving ATOX1 and ATP7B.
Alzheimer's disease
The late-onset type of AD is a disease with a complex etiology. Several hypotheses have been made to explain its onset (Ballard et al., 2011) . The "amyloid cascade" is the most popular hypothesis to date, and several lines of research are contributing new details about the disease pathogenesis (Reitz, 2012) . Oxidative stress is one of the most relevant processes as it damages the AD brain via Fenton and Haber-Weiss chemistry (Jomova et al., 2010) . Different studies indicate that copper can play a key role in these pathogenic processes. A number of molecular studies have also demonstrated that the hypermetallation of Ab peptides can cause oxidative stress, H 2 O 2 production, and Ab plaques (reviewed in Squitti, 2012b) , and clinical, epidemiologic, and meta-analysis studies support these findings (reviewed in Squitti and Polimanti, 2013) .
Although AD shares with WD increased values of non-Cp copper after an overnight fast, thus resembling the same biologic lesion typifying WD, the values are less severe than those of WD. Nevertheless, the correlations with clinical symptoms and markers in the CSF of AD demonstrate a link between copper intoxication and AD (reviewed in Squitti, 2012a) . The increase of non-Cp copper level in the general circulation causes an increase of the non-Cp copper level in the brain (Fig. 3) , as exemplified by WD, and was recently found in postmortem brain samples from AD patients (James et al., 2012) . Non-Cp copper in the brain can likely overwhelm homeostatic processes and trigger the activation of the previously described copper-related amyloid cascade. Although AD cannot be considered the "senile" form of WD, current experimental evidence on copper dyshomeostasis in AD indicates that these disorders share a pathogenetic mechanism. This strongly suggests that current knowledge about WD therapy can be translated into AD prevention or care.
Other diseases
Systemic changes caused by alterations of copper metabolism have been associated with other chronic diseases, for example, diabetes, cardiovascular diseases, and atherosclerosis. Also, an increase in copper levels is established in specific cancers (i.e., breast, cervical, ovarian, lung, prostate, stomach, and leukemia). Apart from inflammatory processes, the association between copper dyshomeostasis and carcinogenesis is likely because of the enhancement of copper-related oxidative stress that is correlated with the activation of several factors involved in the predisposition to tumor onset and progression (e.g., increased basal metabolism, mitochondrial mutations, and cytokines). It has been recently postulated that copper may also be associated with epigenetic changes; disarrangements of copper physiological metabolism may influence gene expression, leading to nonphysiological conditions that may evolve into carcinogenesis.
Patients with diabetes show higher plasma copper concentrations, compared with those of healthy individuals. Accordingly, molecular studies have indicated that copper alterations can interact with glycated proteins in the formation of free radicals and increase oxidative stress. This seems to be in agreement with the relationship between copper overload and presence of diabetes complications (e.g., hypertension and retinopathy).
Copper dyshomeostasis may also be linked to atherosclerosis. The interaction between copper and homocysteine generates free radicals and, consequently, leads to oxidized low-density lipoprotein (Nakano et al., 2004) . The alteration of copper metabolism may also affect endothelial activation by stimulating redoxsensitive cell signaling pathways via redox activity of metal ions (Wei et al., 2012) . Finally, experiments on animal models indicate that copper chelation through tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development (Wei et al., 2012) .
Some disorders caused by acquired copper deficiency include rare diseases of anemia and neutropenia (Wu et al., 2006) . Copper deficiency myelopathy is the most representative copper deficiency-related disease, and risk factors include gastrointestinal surgery, zinc overload, and malabsorption syndromes that are all associated with impaired copper absorption in the upper gastrointestinal tract (Jaiser and Winston, 2010).
Relationship between copper increase and AD risk
Since 2002, we have been carrying out a series of studies investigating the link between copper and AD risk. In these studies, we have analyzed the interplay between copper and other metal markers and the clinical picture of AD. Specifically, we have investigated copper in relation to cognitive performance as measured by the mini-mental state examination and the other tests of the neuropsychological dementia battery, in relation to electroencephalographic examinations, neuroimaging investigations, markers of AD in the CSF, and genetics. From these studies, data have arisen about the risk of developing AD on the basis of a copper dyshomeostasis. Applying models of logistic regression analysis, an increase of 1 mmol/L in total serum copper accounted for 80% of the risk of having AD, as we determined in an initial study (Squitti et al., 2002) . The risk doubles if the comparison is made between AD patients and subjects affected by vascular dementia (Squitti et al., 2003) . In subsequent studies, we focused on non-Cp copper and estimated a higher risk because non-Cp copper increments are more specific for AD than those of total serum copper. A 1 standard deviation increase in non-Cp copper concentration raises the relative risk ratio of developing AD by 3.21 times (95% confidential interval [CI] 1.53e6.71, p < 0.002) (Squitti et al., 2013a) . Moreover, the effect of patients' non-Cp serum copper on the odds of mini-mental state examination worsening in a year was w23% (odds ratio [OR] 1.23, 95% CI 1.03e1.47, p < 0.022) ). The relative risk ratio of having mild cognitive impairment with respect to healthy controls, depending on non-Cp copper increases in serum, has been estimated at w22% ). When we analyzed the possible effects of having specific ATP7B gene variants, we observed a more than two-fold risk of becoming ill with AD comparing carriers with noncarriers (Squitti et al., 2013b) . The values of copper risk reported previously have been estimated based on the entirety of our AD patient cohorts and a comprehensive percentage of AD patients who have not displayed a copper manifestation of the disease. We have estimated that individuals with high serum nonCp copper (>1.6 mmol/L) are 60%e65% of the total sporadic AD population that we have examined for metal studies, which can be approximated at w400 AD patients and 200 mild cognitive impairment subjects (information available at http://www.j-alz. com/letterseditor/index.html#March2013).
Low-copper diet

Copper deficiency and excess in humans and in animal models
Copper toxicity is not a public health concern; there are few toxic threats to human health that are caused by copper (Stern et al., 2007) . However, as mentioned previously, nonphysiological copper abnormalities are associated with relevant health-threatening conditions. The paradigmatic genetic diseases of copper malabsorption and excretion, MD and WD, respectively, exemplify the effects of copper deficiency and excess in the human body and represent the 2 extreme conditions of abnormal copper homeostasis. But what is in the middle? Minor genetic defects in the genes that regulate copper homeostasis can also affect human health. For example, 2 well-established diseases, Indian childhood cirrhosis and idiopathic copper toxicosis, illustrate the interplay between genetic predisposition and environmental copper exposure in determining the onset of copper toxicosis (Muller et al., 1998; Patra et al., 2013) . These are the unique examples of non-Wilsonian copper overload hepatic disorders that are caused by increased dietary copper intake and unidentified genetic defects (Scheinberg and Sternlieb, 1996) .
For humans, the main sources of environmental copper are food and drinking water. In normal environmental conditions, metal absorption via inhalation and skin contact is negligible (de Romana et al., 2011) . However, in individuals with copper metabolism defects, high dietary copper intake can be harmful.
Aged mice fed a copper-deficient diet showed a significant alteration of the concentration of different metal ions (i.e., aluminum, copper, iron, calcium, and zinc) in their brain and other tissues, although they displayed no behavioral changes (Bolognin et al., 2012) . In humans, an acquired copper deficiency is caused mainly by bowel resections, chronic diarrhea, and short bowel syndrome, all of which result in a decrease in intestinal absorption (Btaiche et al., 2011) . In individuals with these malabsorption syndromes, pancytopenia and neurologic dysfunction are the most recurrent clinical manifestations (Prodan et al., 2009) .
As previously mentioned, copper deficiency myelopathy is one of the most representative diseases related to an acquired copper deficiency (Jaiser and Winston, 2010) . Copper supplementation in individuals with an acquired copper deficiency restores normal copper status and prevents deficiency-related adverse sequelae (Prodan et al., 2009 ). Conversely, Long-Evans Cinnamon rats, which are a natural model of WD, have an early and rapid onset of fulminant hepatitis on a high-copper dietary regimen, but they survive long term on a low-copper dietary regimen.
Thus, although a copper overload through high-copper food consumption has little or no direct effect on body copper content under normal physiological conditions (Siaj et al., 2012) (also see Section 2.1), genetic make up can significantly change this scenario because copper intake and genetics are closely connected in terms of copper toxicosis: a high, or even normal, copper dietary intake in individuals with a genetic susceptibility to copper exposure causes metal toxicosis. This is well exemplified in WD and in the Long-Evans Cinnamon rats (through experimental diet manipulations, Brewer, 2012) . From the previous findings, we have postulated that there is a risk of having a specific form of sporadic AD, which we have called "copper AD phenotype," based on a high-moderate dietary copper intake in people prone to a copper genetic susceptibility . The copper genetic susceptibility associated with AD can be thought of as existing between MD and WD. It is not sufficiently severe to cause AD in and of itself, but it can contribute additional altered AD pathways to the disease cascade. Regardless, a low-copper regimen may have a positive effect in controlling this copper risk, and it may even prevent the disease.
Low-copper diet specific for individuals with copper metabolism disarrangements
Regarding essential metals, it is commonly assumed that the dose-response relationship is a U-shaped curve. Many people assume that for copper, in particular, the U-shaped dose-response curve is asymmetric with a steeper relationship for deficiency than for excess (Chambers et al., 2010; Krewski et al., 2010; . Although this copper dose-response is sustained by experimental evidence, it does not take into account the genetics of copper metabolism. Indeed, a number of studies have highlighted the fact that genetics is one of the most important factors in determining individual susceptibility to an environmental exposure (Forsberg et al., 2013; Polimanti et al., 2011; Tenesa and Haley, 2013) .
As previously described, experimental evidence strongly supports the interplay between genetics and dietary copper intake in body copper toxicosis or accumulation in humans. In addition to the established evidence for WD, studies have been conducted in vivo, in vitro, in living patients, and in silico. These studies have demonstrated that AD is also characterized by local and systemic disarrangements in copper metabolism . Molecular studies indicate that this copper phenotype in AD is likely caused by genetic defects in the copper proteins (chaperones and transporters) that control copper homeostasis. Specifically, genetic variants in ATP7B are associated with a significant increase in AD risk (Bucossi et al., 2011 (Bucossi et al., , 2012 (Bucossi et al., , 2013 Squitti and Polimanti, 2012; Squitti et al., 2013b) . Moreover, it has been demonstrated that ATP7B is involved in the modulation of copper dyshomeostasis in AD patients, and carriers of loss-of-function ATP7B variants have higher levels of serum non-Cp copper than noncarriers (Squitti et al., 2013c) . In accordance with these findings, individuals with altered copper pathways (i.e., prone to AD copper risk) can be distinguished from those with normal copper pathways (i.e., not prone to the AD copper risk).
The identification of individuals with a higher AD copper risk can be performed by 1 of 2 approaches. The first is a biochemical method based on the analysis of serum non-Cp copper, looking for values greater than the normal reference value of 1.6 mmol/L. The second approach is based on the sequence analysis of genes involved in copper metabolism (e.g., ATP7B, ATOX1, and COMMD1), identifying the loss-of-function variants that account for the genetic predisposition of copper dyshomeostasis. Unfortunately, current knowledge about copper dyshomeostasis in AD prevents us, at present, from developing a reliable strategy that could be used to identify individuals with a high risk of developing the AD copper phenotype. We are currently working in tandem with other researchers to bridge this gap.
Several studies have attempted to use diet-based approaches to prevent AD (Solfrizzi et al., 2011) ; however, there is a lack of suitable tools that could be used to identify individuals who should be introduced to the diet. Additionally, there is also a lack of markers that could adequately evaluate the efficacy of this dietary intervention. Regarding a low-copper diet, the indirect estimation of non-Cp copper, based on the Walshe formula, is routinely used in clinical practice related to WD (Walshe and Clinical Investigations Standing Committee of the Association of Clinical, 2003), although some theoretical problems preclude its application in certain cases (information available at http://www.j-alz.com/ letterseditor/index.html#March2013). However, a more reliable test is becoming available and is based on the direct measurement of serum non-Cp copper to identify high-risk individuals for a copper dysfunction and to monitor the efficacy of anti-copper therapies. In this regard, it has to be noted that detecting total serum copper, Cp, or non-Cp copper with the Walshe formula in patients taking an anti-copper chelating therapy does not effectively show the bioavailability of copper. In fact, complexes made of copper tightly bound to the chelating agent circulate in the bloodstream and are measured in blood tests, although the copper that they contain is not bioavailable for cell biology processes (Squitti, 2012a) .
Copper dietary intake
As mentioned previously, humans primarily absorb copper through dietary intake. National and international organizations have defined dietary copper reference values to maintain stable copper homeostasis. They also hope to prevent the threatening health conditions linked to its alterations. The WHO defined 0.9e1.3 mg as the minimal copper daily intake (WHO, 1996) . However, the maximum and minimum levels of daily copper intake likely to pose no risk of adverse effects are relative and should be adjusted slightly according to gender and age. To date, no reference values for copper have been determined by WHO for sex and age.
The Food and Nutrition Board of the Institute of Medicine of the National Academies of Sciences provided the references values (recommended dietary allowance, adequate intake, maximum level of daily intake) for dietary copper intake in infants, men, women, and pregnant and lactating women (Table 1) . Particular attention has to be paid to infants and to women who are pregnant or lactating (National Research Council, 2001) . Infants are more susceptible to copper deficiency than adults. Premature infants, in particular, often require more copper at birth than full-term infants because fetuses absorb copper during the last months of pregnancy. In addition, because fetuses absorb copper via the placenta and infants absorb copper via breast milk, pregnant and nursing women require slightly more copper than other women. Moreover, nonnursed infants need to take copper supplements for their first year of life because bovine milk contains low amounts of copper. For men and women with an age between 18 and 70 years, the recommended dietary allowance has been established at 0.9 mg per day (Table 1) .
Copper is a natural element, and it is present in soil and ground water. Although some geographic locations contain significantly more copper than others, drinking water encompasses 20%e25% of the dietary copper ingested by most humans globally. Some authors have recently hypothesized that the copper present in drinking water because of leaching from copper plumbing can increase the risk for AD (Brewer, 2012) .
As drinking water comprises only 25% of the average individual's dietary copper intake, the main source of copper for humans is food (Stern et al., 2007) . The most relevant sources of dietary copper include seafood (especially shellfish), organ meats, grains, and legumes. Furthermore, nuts and certain fruits (e.g., lemons, raisins, coconuts, papaya, and apples) are also rich in copper. Other copper sources include cereals, potatoes, red meat, and mushrooms. Lowcopper foods include tea, rice, and chicken; hence, these foods must be consumed in greater amounts to avoid copper deficiency. Table 2 reports the top 10 foods with the highest content in copper. Cooking, food storage, and food processing also affect the quantity of copper present in any given food. Long-term cooking substantially reduces the copper content in food. For instance, cooking beans result in a 50% reduction in their natural copper content. Also, food processing dramatically affects the copper content. For example, grain conversion to flour results in a reduction of w70%. Another important factor in copper absorption is the acidic environment of the stomach. Individuals with a reduced stomach acid (e.g., hypochlorhydria) may have an increased risk for copper deficiency.
Recent studies have highlighted a potential connection between copper and cholesterol in AD (Hung et al., 2013; Sparks and Schreurs, 2003) . These findings strongly suggest that a diet high in copper and fat can have a strong effect on an individual's susceptibility to AD onset. In accordance with this hypothesis, a high dietary intake of copper and saturated and trans fats has been linked to accelerated cognitive decline (Morris et al., 2006) . Therefore, individuals with a genetic predisposition to copper dyshomeostasis should avoid foods not only rich in copper but also high in fat. Accordingly, to enhance the effectiveness of a low-copper diet, the analysis of serum non-Cp copper should be coupled with the analysis of fat level in the blood (e.g., total cholesterol, high-density lipoproteins, low-density lipoprotein, and triglycerides).
Anti-copper medical foods
In addition to avoiding or limiting the consumption of highcopper foods, researchers have proposed 2 other strategies based on anti-copper medical foods that may reduce the risk of the AD copper phenotype. The first approach involves the ingestion of compounds competitive with copper for intestinal absorption (e.g., zinc). The second approach is based on the use of chelating agents to bind excess copper. However, these compounds bind copper so tightly that they compete with copper proteins and enzymes and cause adverse effects. As such, they should be used only under medical supervision.
Zinc ingestion reduces the body's capacity to absorb copper by potentiating the metallothioneins block in the intestine (see Section 2.1). Zinc can induce a 25-fold increase of the expression of Table 1 Dietary reference intake of copper defined by the Food and Nutrition Board of the Institute of Medicine at the National Academies of Sciences metallothioneins, which tightly bind atoms of copper and trap them into enterocytes, which are eliminated through exfoliation with stools, thus preventing copper transfer into the blood. During therapy with a dosage of 150 mg per day of zinc, body copper balance becomes negative, reverting copper compartmentalization and distribution from the blood to organs and tissues, including the brain. Zinc therapy is currently used to treat WD in clinical practice. It is safer than chelating agents and has about the same efficacy. It is usually proscribed as a form of maintenance therapy, and it is taken by WD patients for the entirety of their lives. Studies on AD patients suggest that zinc therapy may have some efficacy for AD (Brewer, 2012; Constantinidis, 1992; Hoogenraad, 2011) . However, zinc supplementation taken without medical supervision can raise some concerns. Also, the use of oral zinc supplements has been associated with copper deficiency myelopathy, which is an irreversible neurologic syndrome (Gabreyes et al., 2013) . Excess zinc intake because of the chronic use of denture cream may result in hypocupremia and serious neurologic disease (Nations et al., 2008) . Overall, there are great differences in zinc status worldwide because of the variability in diet regimens and in zinc-related policies (WHO, 2013) . It is advisable to monitor zinc supplementation in individuals with copper metabolism abnormalities and to alter monitoring practices as needed in accordance to zinc policies globally.
Conclusions and future perspectives
The present article has reviewed current knowledge about copper dyshomeostasis. It has also explored AD pathogenesis and the interplay between genetics and dietary copper intake in determining susceptibility to the AD copper phenotype. These data strongly support the hypothesis that copper balance is a modifiable factor that could reduce AD risk in certain individuals who can implement a low-copper diet.
Although scientific evidence supporting the detrimental effects of copper on cognition and brain health is mostly consistent, it is not yet conclusive. It will remain inconclusive until the gene mutations that cause copper dysfunction in AD individuals are clearly identified. We believe this identification will occur soon (Squitti et al., 2013c) . However, healthful and inexpensive dietary precautions, monitored by medical professionals (who would introduce a lowcopper diet only to people with confirmed altered copper metabolism), are fully justified and may be currently implemented to safely modify copper-related risk. Specifically, applying the WHO recommendation for a recommended dietary allowance of 0.9 mg per day could be sufficient. Indirect and direct biochemical testing to detect serum non-Cp copper can identify individuals with altered copper metabolism. They can also monitor the effectiveness of a dietary strategy desired to correct this condition. We suggest that individuals with highecopper-related AD risk should adopt a lowcopper diet, that is, increase the quantity of low-copper foods, whereas reducing the quantity of high-copper foods, fatty foods, and alcohol consumption (that affects liver functionality). These individuals should also take zinc supplements, provided this can be done under medical supervision. Although this advice is simple, safe, healthy, and inexpensive, medical supervision is needed to verify the diet's effectiveness and avoid copper deficiency and its adverse sequelae, and such supervision may not be feasible in all locales.
Future perspectives of this dietary strategy involve the improvement of screening tests for individuals with high-copper risk based on genetics and the development of anti-copper medical foods, including, for example, specific zinc supplements. Additionally, an increased understanding of genetics offers us our greatest hope of identifying high-risk individuals. Although genetic studies have indicated that copper-handling genes modulate copper dyshomeostasis in AD, further investigations are needed to enrich our current understanding of the genetics of the AD copper phenotype. Greater understanding could allow us to implement genetic tests that could be used to identify an individual's genetic predisposition.
Anti-copper agents are currently the first line of therapy for treating WD. Little information has been collected about their efficacy to modify the clinical history of AD (as reviewed in Squitti and Salustri, 2009; Squitti and Zito, 2009 ). Hopefully, they will also prove effective in slowing, stopping, or reversing disease progression in AD copper phenotype patients.
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